Alice Rumbold
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alice Rumbold has a total of 277 co-authors. Here are the top co-authors by number of shared publications:
Caroline A Crowther
The University of Auckland; Liggins Institute; Private Bag 92019 85 Park Road Auckland New Zealand
9 shared publications- Vivienne M. Moore
The University of Adelaide
7 shared publications - Michael John Davies
University of Adelaide, Adelaide, Australia
6 shared publications Carmel T Collins
SAHMRI Women and Kids; South Australian Health and Medical Research Institute; North Adelaide Australia
4 shared publications- Lynne C. Giles
Robinson Research Institute and Adelaide Medical School, The University of Adelaide , Adelaide, South Australia
4 shared publications Amy Keir
College of Medicine and Public Health, Flinders University of South Australia, Adelaide, South Australia, Australia
3 shared publications
Latest Publications
- Open Access
Diet Quality and Weight Gain Among Women in the Aboriginal Family Birthing Program in South Australia
Background: This study assessed diet quality and the association between engagement with nutrition support bundles and weight gain among pregnant women having Aboriginal and Torres Strait Islander babies who participated in the Aboriginal Family and Baby Bundles implementation project at two South Australian maternity sites. Methods: Cross-sectional analysis of dietary data was performed using the Australian Recommended Food Score (ARFS) at enrolment, and 24-h food group servings were compared between enrolment and late pregnancy visits. A composite variable for engagement with nutrition support bundles (low vs. high engagement) used initiation, intensity, and duration of engagement criteria. Separate regression models were applied to examine associations between ARFS, adherence to 24-h food serve recommendations, and maternal characteristics at enrolment. An exploratory univariable association between engagement status and gestational weight gain was examined. Results: The median ARFS score at enrolment was 39 (maximum of 62 out of a total of 73). Women aged above 25 years showed significantly higher ARFS compared with those aged 25 years and below (adjusted β coefficient 3.28, 95% CI 0.38, 6.19, p = 0.027). The number of participants meeting the recommended intake of daily fruit serves increased significantly at the late pregnancy visit (McNemar test p value = 0.004). Across pregnancy, consumption of energy-dense soft drinks or snack foods was common (60–68%). Only 15.4% (8/52) of participants showed adequate weight gain, while 26.9% (14/52) showed inadequate weight gain, and 57.7% (30/52) showed excessive weight gain, as per the recommendations for total gestational weight gain. In the high nutrition support engagement group, a higher proportion of adequate weight gain (24.0% vs. 7.4%) and a lower proportion of excessive weight gain were observed (28.0% vs. 85.2%) (p ≤ 0.001) compared with the low engagement group. Conclusions: This study identified sub-optimal diet quality, including high intake of energy-dense food throughout pregnancy and high proportions of inadequate and excessive weight gain among women having Aboriginal babies in South Australia. Further research is needed to determine the most appropriate ways to support healthy eating in pregnancy among women in South Australia.
Open AccessDiet Quality and Weight Gain Among Women in the Aboriginal Family Birthing Program in South Australia
Background: This study assessed diet quality and the association between engagement with nutrition support bundles and weight gain among pregnant women having Aboriginal and Torres Strait Islander babies who participated in the Aboriginal Family and Baby Bundles implementation project at two South Australian maternity sites. Methods: Cross-sectional analysis of dietary data was performed using the Australian Recommended Food Score (ARFS) at enrolment, and 24-h food group servings were compared between enrolment and late pregnancy visits. A composite variable for engagement with nutrition support bundles (low vs. high engagement) used initiation, intensity, and duration of engagement criteria. Separate regression models were applied to examine associations between ARFS, adherence to 24-h food serve recommendations, and maternal characteristics at enrolment. An exploratory univariable association between engagement status and gestational weight gain was examined. Results: The median ARFS score at enrolment was 39 (maximum of 62 out of a total of 73). Women aged above 25 years showed significantly higher ARFS compared with those aged 25 years and below (adjusted β coefficient 3.28, 95% CI 0.38, 6.19, p = 0.027). The number of participants meeting the recommended intake of daily fruit serves increased significantly at the late pregnancy visit (McNemar test p value = 0.004). Across pregnancy, consumption of energy-dense soft drinks or snack foods was common (60–68%). Only 15.4% (8/52) of participants showed adequate weight gain, while 26.9% (14/52) showed inadequate weight gain, and 57.7% (30/52) showed excessive weight gain, as per the recommendations for total gestational weight gain. In the high nutrition support engagement group, a higher proportion of adequate weight gain (24.0% vs. 7.4%) and a lower proportion of excessive weight gain were observed (28.0% vs. 85.2%) (p ≤ 0.001) compared with the low engagement group. Conclusions: This study identified sub-optimal diet quality, including high intake of energy-dense food throughout pregnancy and high proportions of inadequate and excessive weight gain among women having Aboriginal babies in South Australia. Further research is needed to determine the most appropriate ways to support healthy eating in pregnancy among women in South Australia.
- Open Access
- 4 September 2026
- Published by BMJ in Archives of Disease in Childhood - Fetal and Neonatal Edition
Neurodevelopmental impairment and morbidity patterns across two epochs among extremely preterm infant survivors in Australia and New Zealand
Objective: To evaluate neurodevelopmental outcomes at 2–3 years of age among survivors of extremely preterm infant (EPI). Design and setting: Analysis of prospectively collected Australian and New Zealand Neonatal Network data on infants born <28 weeks’ gestation between 2010 and 2019. Main outcome: The prevalence of neurodevelopmental impairment (NDI), defined as any moderate to severe cerebral palsy (CP), sensory impairment or developmental delay (score <70) at 2–3 years of age was determined. Epoch comparisons (2010–204 vs 2015–2019) and the impact of major morbidity on NDI were examined, adjusting for maternal age, antenatal steroids, gestational age, Apgar score, admission temperature, sex and breast milk feeding. Results: Of 6617 EPIs, 15.5% had NDI. Developmental delay was most prevalent (14.5%), including language (11.1%), motor (5.9%), cognitive (5.7%) domains, followed by CP (3.2%), deafness (1.4%) and blindness (0.4%). Compared with infants without morbidity, adjusted odds of NDI increased with one (adjusted OR (aOR) 1.50, 95% CI 1.21 to 1.84), two (aOR 2.09, 95% CI 1.60 to 2.53) and three or more coexisting morbidities (aOR 3.56, 95% CI 2.73 to 4.65). Between epochs, bronchopulmonary dysplasia increased by 6.9% and retinopathy of prematurity by 3.8%, alongside a rise in developmental delay (10.3% to 17.8%), contributing to a 6.6% absolute increase in NDI. Survivors born at 22–23 weeks had the highest NDI rates, increasing from 23.0% to 26.4%. Conclusion: NDI rates among EPI increased over time and were associated with increasing multiple morbidities. Although changes in EPIs survival patterns may have contributed to these trends, reducing neonatal morbidities and strengthening neuroprotective care remain priorities.
- 4 September 2026
- Published by BMJ in Archives of Disease in Childhood - Fetal and Neonatal Edition
Open AccessNeurodevelopmental impairment and morbidity patterns across two epochs among extremely preterm infant survivors in Australia and New Zealand
Objective: To evaluate neurodevelopmental outcomes at 2–3 years of age among survivors of extremely preterm infant (EPI). Design and setting: Analysis of prospectively collected Australian and New Zealand Neonatal Network data on infants born <28 weeks’ gestation between 2010 and 2019. Main outcome: The prevalence of neurodevelopmental impairment (NDI), defined as any moderate to severe cerebral palsy (CP), sensory impairment or developmental delay (score <70) at 2–3 years of age was determined. Epoch comparisons (2010–204 vs 2015–2019) and the impact of major morbidity on NDI were examined, adjusting for maternal age, antenatal steroids, gestational age, Apgar score, admission temperature, sex and breast milk feeding. Results: Of 6617 EPIs, 15.5% had NDI. Developmental delay was most prevalent (14.5%), including language (11.1%), motor (5.9%), cognitive (5.7%) domains, followed by CP (3.2%), deafness (1.4%) and blindness (0.4%). Compared with infants without morbidity, adjusted odds of NDI increased with one (adjusted OR (aOR) 1.50, 95% CI 1.21 to 1.84), two (aOR 2.09, 95% CI 1.60 to 2.53) and three or more coexisting morbidities (aOR 3.56, 95% CI 2.73 to 4.65). Between epochs, bronchopulmonary dysplasia increased by 6.9% and retinopathy of prematurity by 3.8%, alongside a rise in developmental delay (10.3% to 17.8%), contributing to a 6.6% absolute increase in NDI. Survivors born at 22–23 weeks had the highest NDI rates, increasing from 23.0% to 26.4%. Conclusion: NDI rates among EPI increased over time and were associated with increasing multiple morbidities. Although changes in EPIs survival patterns may have contributed to these trends, reducing neonatal morbidities and strengthening neuroprotective care remain priorities.
- 1 September 2026
- Published by BMJ in Archives of Disease in Childhood - Fetal and Neonatal Edition
Effect of brewers’ yeast or beta-glucan derived from Saccharomyces cerevisiae on breast milk supply following preterm birth: the BLOOM randomised controlled trial
Objective: Breast milk is the optimal source of nutrition for preterm infants; however, low breast milk production is common following a preterm birth. This study aimed to determine if taking brewers’ yeast or beta-glucan improves daily expressed breast milk volume. Design: Randomised, blinded, parallel, placebo-controlled trial. Setting: Three Australian tertiary-level neonatal units. Patients: Mothers with a singleton or twin pregnancy who gave birth at <34 weeks’ gestation. Interventions: Mothers were randomised within 72 hours of birth into three parallel groups in a 1:1:1 ratio to receive either brewers’ yeast, beta-glucan or placebo capsules for 7 days. Main outcome measure: Total expressed breast milk volume over a 24-hour period on day 7 of intervention. Results: A total of 105 mothers underwent randomisation between August 2022 and April 2024 (36 brewers’ yeast, 35 beta-glucan and 34 placebo). The adjusted mean difference in daily expressed breast milk volume was 94 mL/day (95% CI −51 mL/day to 239 mL/day) between the brewers’ yeast and placebo groups and −25 mL/day (95% CI −173 mL/day to 123 mL/day) between the beta-glucan and placebo groups. Maternal side effects were similar across groups. Conclusion: We found no clear effect of short-term administration of brewers’ yeast or beta-glucan on breast-milk production following preterm birth; both interventions were well tolerated. Given the small sample size, these findings do not rule out the possibility of a clinically meaningful benefit of brewers’ yeast and suggest further research with a larger sample size may be warranted to clarify the potential clinical impact. Trial registration number: ACTRN12622000968774.
- 1 September 2026
- Published by BMJ in Archives of Disease in Childhood - Fetal and Neonatal Edition
Effect of brewers’ yeast or beta-glucan derived from Saccharomyces cerevisiae on breast milk supply following preterm birth: the BLOOM randomised controlled trial
Objective: Breast milk is the optimal source of nutrition for preterm infants; however, low breast milk production is common following a preterm birth. This study aimed to determine if taking brewers’ yeast or beta-glucan improves daily expressed breast milk volume. Design: Randomised, blinded, parallel, placebo-controlled trial. Setting: Three Australian tertiary-level neonatal units. Patients: Mothers with a singleton or twin pregnancy who gave birth at <34 weeks’ gestation. Interventions: Mothers were randomised within 72 hours of birth into three parallel groups in a 1:1:1 ratio to receive either brewers’ yeast, beta-glucan or placebo capsules for 7 days. Main outcome measure: Total expressed breast milk volume over a 24-hour period on day 7 of intervention. Results: A total of 105 mothers underwent randomisation between August 2022 and April 2024 (36 brewers’ yeast, 35 beta-glucan and 34 placebo). The adjusted mean difference in daily expressed breast milk volume was 94 mL/day (95% CI −51 mL/day to 239 mL/day) between the brewers’ yeast and placebo groups and −25 mL/day (95% CI −173 mL/day to 123 mL/day) between the beta-glucan and placebo groups. Maternal side effects were similar across groups. Conclusion: We found no clear effect of short-term administration of brewers’ yeast or beta-glucan on breast-milk production following preterm birth; both interventions were well tolerated. Given the small sample size, these findings do not rule out the possibility of a clinically meaningful benefit of brewers’ yeast and suggest further research with a larger sample size may be warranted to clarify the potential clinical impact. Trial registration number: ACTRN12622000968774.
- Open Access
- 20 March 2026
- Published by International Society of Global Health in Journal of Global Health
- Vol. 16, 04088
Antenatal magnesium sulphate for preterm foetal neuroprotection in low- and middle-income countries: a scoping review of research studies and guidelines
Cerebral palsy (CP) is a life-long physical disability. This disorder of movement and posture leads to limitations in activity [1,2], and may be accompanied by disorders of sensation, cognition, communication, behaviour, epilepsy and pain [1,3]. Global estimates of CP indicate a recent decline in birth prevalence in high-income countries (HICs) to 1.6 per 1000 […]
- 20 March 2026
- Published by International Society of Global Health in Journal of Global Health
- Vol. 16, 04088
Open AccessAntenatal magnesium sulphate for preterm foetal neuroprotection in low- and middle-income countries: a scoping review of research studies and guidelines
Cerebral palsy (CP) is a life-long physical disability. This disorder of movement and posture leads to limitations in activity [1,2], and may be accompanied by disorders of sensation, cognition, communication, behaviour, epilepsy and pain [1,3]. Global estimates of CP indicate a recent decline in birth prevalence in high-income countries (HICs) to 1.6 per 1000 […]
- Open Access
- 1 October 2025
- Published by American Medical Association (AMA) in JAMA Pediatrics
- Vol. 179 (10) , 1065
Supplemental Donor Milk vs Infant Formula in Moderate to Late Preterm Infants
Importance: High-quality evidence supports the use of pasteurized donor human milk (donor milk) in very preterm infants with insufficient maternal milk available. However, evidence to guide the use of donor milk in more mature preterm infants is lacking.Objective: To compare the effect of donor milk vs term infant formula, used to supplement insufficient maternal milk, on the time to establish full enteral feeds in moderate to late preterm infants.Design, Setting, and Participants: This multisite, blinded randomized clinical trial was conducted from July 6, 2021, to April 5, 2023, at 2 Australian neonatal units. Infants 4 days old or younger, born between 32 + 0 and 36 + 6 weeks’ gestation, with a birth weight of 1500 g or higher, and admitted to a neonatal unit were eligible if they were clinically stable, ready to commence or had commenced enteral feeds, and had insufficient maternal milk available. Infants were followed up until 6-month corrected age (CA). Follow-up assessments until 6-month CA were completed by December 4, 2023, and data analyses were completed by January 23, 2025.Intervention: Infants were randomly assigned to receive supplemental donor milk or term formula for up to 8 days, stratified by site and gestational age at birth.Main Outcomes and Measures: The primary outcome was time to full enteral feeds (defined as 150 mL/kg/day). Secondary outcomes included feed intolerance, growth, body composition, breast milk feeding, and hospital readmissions to 6-month CA.Results: Of 201 infants randomized (99 to donor milk, 102 to formula), the mean (SD) birth gestational age was 34.6 (1.2) weeks, mean (SD) birth weight was 2267.1 (450.8) g, 88 infants (43.8%) were female, and 75 infants (37.3%) were a twin or triplet. Mean (SD) time to reach full enteral feeds did not differ between groups (donor milk group: 5.7 [2.6] days; formula group: 5.8 [3.4] days; adjusted mean difference, −0.07; 95% CI, −0.90 to 0.76). Secondary outcomes were similar between groups, except that infants in the donor milk group had a lower rate of birth weight regain compared with the formula group (mean [SD] time to regain in donor milk group: 10.7 [5.7] days; formula group: 8.4 [4.4] days; hazard ratio, 0.65; 95% CI, 0.47-0.88).Conclusions and Relevance: In this multisite randomized clinical trial, supplemental donor milk did not reduce time to full enteral feeds in moderate to late preterm infants compared with term formula for up to 8 days.Trial Registration: anzctr.org.au Identifier: ACTRN12621000529842
- 1 October 2025
- Published by American Medical Association (AMA) in JAMA Pediatrics
- Vol. 179 (10) , 1065
Open AccessSupplemental Donor Milk vs Infant Formula in Moderate to Late Preterm Infants
Importance: High-quality evidence supports the use of pasteurized donor human milk (donor milk) in very preterm infants with insufficient maternal milk available. However, evidence to guide the use of donor milk in more mature preterm infants is lacking.Objective: To compare the effect of donor milk vs term infant formula, used to supplement insufficient maternal milk, on the time to establish full enteral feeds in moderate to late preterm infants.Design, Setting, and Participants: This multisite, blinded randomized clinical trial was conducted from July 6, 2021, to April 5, 2023, at 2 Australian neonatal units. Infants 4 days old or younger, born between 32 + 0 and 36 + 6 weeks’ gestation, with a birth weight of 1500 g or higher, and admitted to a neonatal unit were eligible if they were clinically stable, ready to commence or had commenced enteral feeds, and had insufficient maternal milk available. Infants were followed up until 6-month corrected age (CA). Follow-up assessments until 6-month CA were completed by December 4, 2023, and data analyses were completed by January 23, 2025.Intervention: Infants were randomly assigned to receive supplemental donor milk or term formula for up to 8 days, stratified by site and gestational age at birth.Main Outcomes and Measures: The primary outcome was time to full enteral feeds (defined as 150 mL/kg/day). Secondary outcomes included feed intolerance, growth, body composition, breast milk feeding, and hospital readmissions to 6-month CA.Results: Of 201 infants randomized (99 to donor milk, 102 to formula), the mean (SD) birth gestational age was 34.6 (1.2) weeks, mean (SD) birth weight was 2267.1 (450.8) g, 88 infants (43.8%) were female, and 75 infants (37.3%) were a twin or triplet. Mean (SD) time to reach full enteral feeds did not differ between groups (donor milk group: 5.7 [2.6] days; formula group: 5.8 [3.4] days; adjusted mean difference, −0.07; 95% CI, −0.90 to 0.76). Secondary outcomes were similar between groups, except that infants in the donor milk group had a lower rate of birth weight regain compared with the formula group (mean [SD] time to regain in donor milk group: 10.7 [5.7] days; formula group: 8.4 [4.4] days; hazard ratio, 0.65; 95% CI, 0.47-0.88).Conclusions and Relevance: In this multisite randomized clinical trial, supplemental donor milk did not reduce time to full enteral feeds in moderate to late preterm infants compared with term formula for up to 8 days.Trial Registration: anzctr.org.au Identifier: ACTRN12621000529842
- Open Access
- 22 August 2025
- Published by Elsevier in Women and Birth
- Vol. 38 (5) , 101960
Improving support for successful breastfeeding initiation and duration – Recommendations from mothers of Aboriginal infants
- 22 August 2025
- Published by Elsevier in Women and Birth
- Vol. 38 (5) , 101960
Open AccessImproving support for successful breastfeeding initiation and duration – Recommendations from mothers of Aboriginal infants
- 13 May 2025
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2025 (5) , CD003743
Early discharge with home support of gavage feeding for stable preterm infants who have not established full oral feeds
Many preterm infants otherwise ready for discharge remain hospitalised while they transition from gavage to full sucking feeds. Early discharge of stable preterm infants still requiring gavage feeds may have some benefits: it could reduce separation of parents and infants and reduce costs to the healthcare system and families compared with discharge home when on full sucking feeds. Potential disadvantages of early discharge include increased care burden for the family and the risk of complications related to gavage feeding. This is an update of a review first published in 2003 and last updated in 2015. To assess the effectiveness and safety of early discharge with home support of gavage feeding for stable preterm infants who have not established full oral feeds compared with later discharge when full sucking feeds have been established. We searched CENTRAL, MEDLINE, Embase, CINAHL, and trial registries up to May 2024. We checked the reference lists of included studies and relevant systematic reviews. We included randomised controlled trials (RCTs) and quasi-RCTs that enroled infants born before 37 weeks who required no intravenous nutrition at the time of discharge. The comparison of interest was early discharge home with gavage feeds and healthcare support versus later discharge home after attainment of full sucking feeds. Critical outcomes were time to reach full sucking feeds, weight gain at latest time point measured, and breastfeeding on discharge from home support or hospital. Important outcomes included infection up to discharge (e.g. respiratory infections, use of intravenous antibiotics), breastfeeding at three months after discharge, rehospitalisation up to 12 months after discharge, and composite neurodevelopmental outcome at 12 months or later. Two review authors independently screened and selected trials, extracted data, and assessed the risk of bias using the Cochrane risk of bias tool RoB 1. We presented dichotomous data as summary risk ratios (RRs) with 95% confidence intervals (CIs), and continuous data as mean differences (MDs) with 95% CIs. We used the GRADE approach to assess the certainty of the evidence. There were no new studies available for inclusion in this update. As in the original review, we included one quasi-RCT (88 infants, 75 families) evaluating early discharge with home support of gavage feeding (early discharge with support) versus later discharge on full sucking feeds (later discharge) in physiologically stable preterm infants born before 37 weeks' gestation with an anticipated need for special care for at least one additional week. The study was conducted in Sweden in the 1990s. Critical outcomes Time to reach full sucking feeds was not reported. Early discharge with support compared with later discharge may have little or no effect on daily weight gain from trial entry to discharge from home support or hospital, but the evidence is very uncertain (MD -1.10 g/day, 95% CI -3.94 to 1.74; 88 infants). Early discharge with support compared with later discharge may have little or no effect on the risk of stopping any breastfeeding (RR 0.50, 95% CI 0.10 to 2.58; 82 infants) and stopping fully breastfeeding (RR 1.30, 95% CI 0.64 to 2.62; 82 infants) on discharge from home support or hospital, but the evidence is very uncertain. Important outcomes Early discharge with support compared with later discharge may reduce the risk of respiratory infections (RR 0.36, 95% CI 0.15 to 0.83; 88 infants) and may have little or no effect on intravenous antibiotic use (RR 0.19, 95% CI 0.01 to 3.87; 88 infants) up to discharge from home support or hospital, but the evidence for both outcomes is very uncertain. Early discharge with support compared with later discharge may have little or no effect on the risk of stopping any breastfeeding (RR 1.60, 95% CI 0.57 to 4.48; 82 infants) or fully breastfeeding (RR 1.33, 95% CI 0.51 to 3.50; 82 infants) at three months after discharge from home support or hospital, but the evidence is very uncertain. Early discharge with support compared with later discharge may have little or no effect on the need for rehospitalisation during the 12 months after discharge from home support or hospital, but the evidence is very uncertain (RR 1.09, 95% CI 0.54 to 2.18; 82 infants). The included study did not report a composite neurodevelopmental outcome at 12 months or later. Certainty of the evidence We rated the certainty of the evidence as very low for all outcomes due to risk of bias concerns and the imprecision of effect estimates from this small study. The currently available evidence, from one small quasi-RCT conducted in the 1990s, indicates early discharge with home support of gavage feeding compared with later discharge on full sucking feeds may result in little to no difference in weight gain up to discharge from home support/hospital, breastfeeding at discharge and at three months, and rehospitalisation up to 12 months. Early discharge with support versus later discharge may reduce the risk of respiratory infections but result in little to no difference in intravenous antibiotic use up to discharge from home support/hospital. The evidence for all outcomes is very uncertain. There is a need for high-quality RCTs to determine the benefits and harms of early discharge with home support for stable preterm infants in diverse settings and populations. The two ongoing studies (one completed but unpublished, the other with an unclear status) may contribute to addressing some of these gaps. The review authors received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors for their work on this review update. The 2003 and 2015 versions are available via 10.1002/14651858.CD003743 and 10.1002/14651858.CD003743.pub2.
- 13 May 2025
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2025 (5) , CD003743
Early discharge with home support of gavage feeding for stable preterm infants who have not established full oral feeds
Many preterm infants otherwise ready for discharge remain hospitalised while they transition from gavage to full sucking feeds. Early discharge of stable preterm infants still requiring gavage feeds may have some benefits: it could reduce separation of parents and infants and reduce costs to the healthcare system and families compared with discharge home when on full sucking feeds. Potential disadvantages of early discharge include increased care burden for the family and the risk of complications related to gavage feeding. This is an update of a review first published in 2003 and last updated in 2015. To assess the effectiveness and safety of early discharge with home support of gavage feeding for stable preterm infants who have not established full oral feeds compared with later discharge when full sucking feeds have been established. We searched CENTRAL, MEDLINE, Embase, CINAHL, and trial registries up to May 2024. We checked the reference lists of included studies and relevant systematic reviews. We included randomised controlled trials (RCTs) and quasi-RCTs that enroled infants born before 37 weeks who required no intravenous nutrition at the time of discharge. The comparison of interest was early discharge home with gavage feeds and healthcare support versus later discharge home after attainment of full sucking feeds. Critical outcomes were time to reach full sucking feeds, weight gain at latest time point measured, and breastfeeding on discharge from home support or hospital. Important outcomes included infection up to discharge (e.g. respiratory infections, use of intravenous antibiotics), breastfeeding at three months after discharge, rehospitalisation up to 12 months after discharge, and composite neurodevelopmental outcome at 12 months or later. Two review authors independently screened and selected trials, extracted data, and assessed the risk of bias using the Cochrane risk of bias tool RoB 1. We presented dichotomous data as summary risk ratios (RRs) with 95% confidence intervals (CIs), and continuous data as mean differences (MDs) with 95% CIs. We used the GRADE approach to assess the certainty of the evidence. There were no new studies available for inclusion in this update. As in the original review, we included one quasi-RCT (88 infants, 75 families) evaluating early discharge with home support of gavage feeding (early discharge with support) versus later discharge on full sucking feeds (later discharge) in physiologically stable preterm infants born before 37 weeks' gestation with an anticipated need for special care for at least one additional week. The study was conducted in Sweden in the 1990s. Critical outcomes Time to reach full sucking feeds was not reported. Early discharge with support compared with later discharge may have little or no effect on daily weight gain from trial entry to discharge from home support or hospital, but the evidence is very uncertain (MD -1.10 g/day, 95% CI -3.94 to 1.74; 88 infants). Early discharge with support compared with later discharge may have little or no effect on the risk of stopping any breastfeeding (RR 0.50, 95% CI 0.10 to 2.58; 82 infants) and stopping fully breastfeeding (RR 1.30, 95% CI 0.64 to 2.62; 82 infants) on discharge from home support or hospital, but the evidence is very uncertain. Important outcomes Early discharge with support compared with later discharge may reduce the risk of respiratory infections (RR 0.36, 95% CI 0.15 to 0.83; 88 infants) and may have little or no effect on intravenous antibiotic use (RR 0.19, 95% CI 0.01 to 3.87; 88 infants) up to discharge from home support or hospital, but the evidence for both outcomes is very uncertain. Early discharge with support compared with later discharge may have little or no effect on the risk of stopping any breastfeeding (RR 1.60, 95% CI 0.57 to 4.48; 82 infants) or fully breastfeeding (RR 1.33, 95% CI 0.51 to 3.50; 82 infants) at three months after discharge from home support or hospital, but the evidence is very uncertain. Early discharge with support compared with later discharge may have little or no effect on the need for rehospitalisation during the 12 months after discharge from home support or hospital, but the evidence is very uncertain (RR 1.09, 95% CI 0.54 to 2.18; 82 infants). The included study did not report a composite neurodevelopmental outcome at 12 months or later. Certainty of the evidence We rated the certainty of the evidence as very low for all outcomes due to risk of bias concerns and the imprecision of effect estimates from this small study. The currently available evidence, from one small quasi-RCT conducted in the 1990s, indicates early discharge with home support of gavage feeding compared with later discharge on full sucking feeds may result in little to no difference in weight gain up to discharge from home support/hospital, breastfeeding at discharge and at three months, and rehospitalisation up to 12 months. Early discharge with support versus later discharge may reduce the risk of respiratory infections but result in little to no difference in intravenous antibiotic use up to discharge from home support/hospital. The evidence for all outcomes is very uncertain. There is a need for high-quality RCTs to determine the benefits and harms of early discharge with home support for stable preterm infants in diverse settings and populations. The two ongoing studies (one completed but unpublished, the other with an unclear status) may contribute to addressing some of these gaps. The review authors received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors for their work on this review update. The 2003 and 2015 versions are available via 10.1002/14651858.CD003743 and 10.1002/14651858.CD003743.pub2.
- Open Access
- 22 October 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (7) , 1818-1827
Clomiphene Citrate Medication for Infertility and Risk of Stillbirth or Neonatal Death: A Population-based Cohort Study
Objective: To assess associations between clomiphene citrate (CC) use and perinatal death. Design: Whole of population data linkage cohort. Setting: South Australia. Participants: All women giving birth between July 2003 and December 2015 (n = 242,077). Methods: All births of at least 20 weeks were linked to government records of dispensed medications. A pregnancy was considered exposed to CC if a prescription was dispensed from 90 days before through to the end of a conception window. Descriptive statistics for stillbirths and neonatal deaths were stratified by multiplicity. For singletons, multivariable logistic regression models were used to examine the association of CC exposure with the combined outcome of perinatal death. Main outcome measures: Stillbirths and neonatal deaths (with 28 days of birth) combined as perinatal deaths. Results: Among singletons, the prevalence of stillbirth was 6.6 per 1000 births, with neonatal deaths of 2.1 per 1000 live births. Among singletons conceived with CC, stillbirth and neonatal death had a prevalence of 10.2 and 3.1 per 1000, respectively. For the combined outcome of perinatal death, the odds ratio was 1.54 (95% confidence interval 1.15, 2.07), stable upon adjustment for factors conveying biological (eg, obesity, pregestational diabetes) and social (eg, disadvantage) risks for perinatal death. Conclusion: Risk of perinatal death may be increased in pregnancies that follow use of CC. While established confounding factors related to infertility were taken into account, there may be some residual contribution of underlying infertility.
- 22 October 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (7) , 1818-1827
Open AccessClomiphene Citrate Medication for Infertility and Risk of Stillbirth or Neonatal Death: A Population-based Cohort Study
Objective: To assess associations between clomiphene citrate (CC) use and perinatal death. Design: Whole of population data linkage cohort. Setting: South Australia. Participants: All women giving birth between July 2003 and December 2015 (n = 242,077). Methods: All births of at least 20 weeks were linked to government records of dispensed medications. A pregnancy was considered exposed to CC if a prescription was dispensed from 90 days before through to the end of a conception window. Descriptive statistics for stillbirths and neonatal deaths were stratified by multiplicity. For singletons, multivariable logistic regression models were used to examine the association of CC exposure with the combined outcome of perinatal death. Main outcome measures: Stillbirths and neonatal deaths (with 28 days of birth) combined as perinatal deaths. Results: Among singletons, the prevalence of stillbirth was 6.6 per 1000 births, with neonatal deaths of 2.1 per 1000 live births. Among singletons conceived with CC, stillbirth and neonatal death had a prevalence of 10.2 and 3.1 per 1000, respectively. For the combined outcome of perinatal death, the odds ratio was 1.54 (95% confidence interval 1.15, 2.07), stable upon adjustment for factors conveying biological (eg, obesity, pregestational diabetes) and social (eg, disadvantage) risks for perinatal death. Conclusion: Risk of perinatal death may be increased in pregnancies that follow use of CC. While established confounding factors related to infertility were taken into account, there may be some residual contribution of underlying infertility.
- Open Access
Maternal modifiable factors and risk of congenital heart defects: systematic review and causality assessment
Objective Primary prevention strategies are critical to reduce the global burden of congenital heart defects (CHDs); this requires robust knowledge of causal agents. We aimed to review associations between CHDs and maternal advanced age, obesity, diabetes, hypertension, smoking and alcohol consumption and assess the causal nature of the associations. Design Systematic review of reviews with application of a Bradford Hill criteria score-based causal assessment system. Data sources We searched PubMed, Embase and Episteminokos (January 1990–April 2023). Eligibility criteria Systematic reviews of original epidemiological studies reporting association (relative risk) between one or more of the above maternal factors and CHDs overall (any type) in subsequent offspring. Data extraction and synthesis Two independent reviewers selected eligible reviews, assessed the risk of bias and assigned the strength of evidence for causality. Results There was strong evidence of a causal relationship between CHDs and maternal obesity (prepregnancy and early pregnancy) and pre-existing diabetes (six of seven Bradford Hill criteria met). For pre-existing hypertension (strength and biological gradient not met), and advanced age (strength, consistency and biological gradient not met), causal evidence was moderate. Evidence for the causal contribution of gestational diabetes, gestational hypertension, smoking and alcohol consumption was weak (strength, consistency, temporality and biological gradient not met). Conclusions CHDs can be reduced with stronger action to reduce maternal obesity and pre-existing diabetes prevalence. Investigating environmental exposures that have received limited attention, such as air pollutants and chemical exposures, is important to further inform prevention.
Open AccessMaternal modifiable factors and risk of congenital heart defects: systematic review and causality assessment
Objective Primary prevention strategies are critical to reduce the global burden of congenital heart defects (CHDs); this requires robust knowledge of causal agents. We aimed to review associations between CHDs and maternal advanced age, obesity, diabetes, hypertension, smoking and alcohol consumption and assess the causal nature of the associations. Design Systematic review of reviews with application of a Bradford Hill criteria score-based causal assessment system. Data sources We searched PubMed, Embase and Episteminokos (January 1990–April 2023). Eligibility criteria Systematic reviews of original epidemiological studies reporting association (relative risk) between one or more of the above maternal factors and CHDs overall (any type) in subsequent offspring. Data extraction and synthesis Two independent reviewers selected eligible reviews, assessed the risk of bias and assigned the strength of evidence for causality. Results There was strong evidence of a causal relationship between CHDs and maternal obesity (prepregnancy and early pregnancy) and pre-existing diabetes (six of seven Bradford Hill criteria met). For pre-existing hypertension (strength and biological gradient not met), and advanced age (strength, consistency and biological gradient not met), causal evidence was moderate. Evidence for the causal contribution of gestational diabetes, gestational hypertension, smoking and alcohol consumption was weak (strength, consistency, temporality and biological gradient not met). Conclusions CHDs can be reduced with stronger action to reduce maternal obesity and pre-existing diabetes prevalence. Investigating environmental exposures that have received limited attention, such as air pollutants and chemical exposures, is important to further inform prevention.
- 4 March 2024
- Published by Taylor & Francis in Sex Education
- Vol. 25 (2) , 273-289
‘It’s complicated’: young people’s views on the complexity of asking for consent and the role for sex and relationships education
- 4 March 2024
- Published by Taylor & Francis in Sex Education
- Vol. 25 (2) , 273-289
‘It’s complicated’: young people’s views on the complexity of asking for consent and the role for sex and relationships education